Published in Rev Infect Dis on January 07, 1992
From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol (2010) 3.46
Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol (2003) 2.51
Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med (2012) 2.29
Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis (2011) 2.14
Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immun (2001) 2.09
Global eradication of poliomyelitis: benefit-cost analysis. Bull World Health Organ (1996) 1.99
Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev (2004) 1.95
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol (2010) 1.83
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog (2012) 1.50
Do antenatal parasite infections devalue childhood vaccination? PLoS Negl Trop Dis (2009) 1.43
Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin (2010) 1.39
Predictive spatial risk model of poliovirus to aid prioritization and hasten eradication in Nigeria. BMC Med (2014) 1.35
The role of research in viral disease eradication and elimination programs: lessons for malaria eradication. PLoS Med (2011) 1.34
Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun (2011) 1.23
The role of older children and adults in wild poliovirus transmission. Proc Natl Acad Sci U S A (2014) 1.23
Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ (1994) 1.20
The final stages of the global eradication of poliomyelitis. Philos Trans R Soc Lond B Biol Sci (2013) 1.18
Seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China. Clin Vaccine Immunol (2013) 1.18
The effect of rotavirus vaccine on diarrhoea mortality. Int J Epidemiol (2010) 1.17
Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc Natl Acad Sci U S A (2014) 1.16
Impact of early life exposures to geohelminth infections on the development of vaccine immunity, allergic sensitization, and allergic inflammatory diseases in children living in tropical Ecuador: the ECUAVIDA birth cohort study. BMC Infect Dis (2011) 1.11
Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ (1994) 1.08
Estimating the extent of vaccine-derived poliovirus infection. PLoS One (2008) 1.05
Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt. Bull World Health Organ (1995) 1.03
Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis. J Infect Dis (2014) 1.02
Should the human microbiome be considered when developing vaccines? PLoS Pathog (2010) 1.01
Polio eradication as 2000 approaches. BMJ (1992) 0.99
Complex adaptive immunity to enteric fevers in humans: lessons learned and the path forward. Front Immunol (2014) 0.99
Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin Vaccine Immunol (2012) 0.98
Environmental enteric dysfunction: an overview. Food Nutr Bull (2015) 0.97
Surveillance for the Expanded Programme on Immunization. Bull World Health Organ (1993) 0.95
Genomic characterization of human and environmental polioviruses isolated in Albania. Appl Environ Microbiol (1999) 0.94
Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bull World Health Organ (1992) 0.90
Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Bull World Health Organ (1996) 0.88
Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLoS One (2015) 0.88
Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus. BMC Public Health (2013) 0.86
Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya. PLoS Negl Trop Dis (2015) 0.85
The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis (2015) 0.84
Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana. Bull World Health Organ (1995) 0.83
Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One (2012) 0.83
Sero-survey of polio antibodies during wild poliovirus outbreak in southern Xinjiang Uygur Autonomous Region, China. PLoS One (2014) 0.83
Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame. PLoS Pathog (2016) 0.82
An evolving perspective about the origins of childhood undernutrition and nutritional interventions that includes the gut microbiome. Ann N Y Acad Sci (2014) 0.82
Pediatric small intestine bacterial overgrowth in low-income countries. Trends Mol Med (2014) 0.80
A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine (2013) 0.80
Measuring polio immunity to plan immunization activities. Vaccine (2016) 0.80
Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil's National Immunization Program. J Infect Dis (2014) 0.79
Maternal Helminth Infection Is Associated With Higher Infant Immunoglobulin A Titers to Antigen in Orally Administered Vaccines. J Infect Dis (2016) 0.79
Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania. Vaccine (2013) 0.79
Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Bull World Health Organ (1995) 0.79
Estimating the risk of re-emergence after stopping polio vaccination. Front Microbiol (2012) 0.79
Probiotics, antibiotics and the immune responses to vaccines. Philos Trans R Soc Lond B Biol Sci (2015) 0.78
Oral and inactivated poliovirus vaccines in the newborn: a review. Vaccine (2012) 0.78
A spatial model of Wild Poliovirus Type 1 in Kano State, Nigeria: calibration and assessment of elimination probability. BMC Infect Dis (2016) 0.77
Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines. Hum Vaccin Immunother (2014) 0.77
Helminth-Tuberculosis Co-infection: An Immunologic Perspective. Trends Immunol (2016) 0.77
A Single Dose of Oral BCG Moreau Fails to Boost Systemic IFN-γ Responses to Tuberculin in Children in the Rural Tropics: Evidence for a Barrier to Mucosal Immunization. J Trop Med (2012) 0.76
Vaccines against human diarrheal pathogens: current status and perspectives. Hum Vaccin Immunother (2014) 0.76
Microbiota Influences Vaccine and Mucosal Adjuvant Efficacy. Immune Netw (2017) 0.75
Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies. Heliyon (2017) 0.75
Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants. Vaccine (2016) 0.75
Biological challenges to effective vaccines in the developing world. Philos Trans R Soc Lond B Biol Sci (2015) 0.75
Partition and poliomyelitis: an investigation of the polio disparity affecting Muslims during India's eradication program. PLoS One (2015) 0.75
The WHO Global Programme for Vaccines and Immunization Vaccine Trial Registry. Bull World Health Organ (1997) 0.75
Eradicating polio in Pakistan: an analysis of the challenges and solutions to this security and health issue. Global Health (2016) 0.75
AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns. AAPS PharmSci (2003) 0.75
Determinants of effective vaccine coverage in low and middle-income countries: a systematic review and interpretive synthesis. BMC Health Serv Res (2017) 0.75
Polio immunity and the impact of mass immunization campaigns in the Democratic Republic of the Congo. Vaccine (2017) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med (2000) 8.46
Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr (2000) 4.08
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
Evaluation of simple clinical signs for the diagnosis of acute lower respiratory tract infection. Lancet (1988) 3.12
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Immune response to intradermally injected inactivated poliovirus vaccine. Lancet (1991) 2.57
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol (1979) 2.25
Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ (2008) 2.16
Effect of breast-feeding on seroresponse of infants to oral poliovirus vaccination. Pediatrics (1976) 2.15
Tuberculosis control, without protection from BCG. Indian Pediatr (2000) 2.14
Evidence for HTLV-III infection in prostitutes in Tamil Nadu (India). Indian J Med Res (1987) 2.13
Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis (1997) 2.12
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol (1972) 2.08
Comparison of competitive and indirect enzyme-linked immunosorbent assays for detection of bluetongue virus antibodies in serum and whole blood. J Clin Microbiol (1987) 2.07
Prevalence of HIV infection in risk groups in Tamilnadu, India. Lancet (1987) 2.03
No seroconversion after hepatitis B immunization. Indian Pediatr (1997) 2.03
India's polio eradication efforts at cross roads. Indian Pediatr (1998) 1.98
Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol (1980) 1.97
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Antibody response of infants in tropics to five doses of oral polio vaccine. Br Med J (1976) 1.94
Temperature-sensitive mutants of respiratory syncytial virus. J Virol (1969) 1.94
Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J (2001) 1.90
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
A review of human immunodeficiency virus infection in India. J Acquir Immune Defic Syndr (1994) 1.88
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr (2000) 1.85
Clinical and laboratory profile of AIDS in India. J Acquir Immune Defic Syndr (1992) 1.83
Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis (1994) 1.78
Adenovirus infections in young children. Pediatrics (1985) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis (1995) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Hepatitis B in India: a review of disease epidemiology. Indian Pediatr (2001) 1.66
Cytomegalovirus pneumonia in two infants recently adopted from China. Clin Infect Dis (1999) 1.65
The natural history of human immunodeficiency virus 1 infection in Haitian infants. Pediatr Infect Dis J (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61
Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis (1982) 1.61
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol (1985) 1.59
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis (1988) 1.52
Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics (1997) 1.51
Temperature-sensitive mutants of respiratory syncytial virus: in-vivo studies in hamsters. J Infect Dis (1970) 1.51
Paralytic poliomyelitis: clinical and virological studies. Indian Pediatr (1973) 1.50
Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. J Infect Dis (1980) 1.47
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2). J Pediatr (1975) 1.45
Epidemiology of HIV and AIDS in India. AIDS (1994) 1.43
Candidate AIDS vaccines. N Engl J Med (1995) 1.41
Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis (1983) 1.41
Mother-to-child transmission of HIV must be prevented. Indian Pediatr (2001) 1.40
Method to increase the sensitivity of poliovirus isolation. Lancet (1992) 1.39
BCG vaccination: some practical dilemmas. Indian Pediatr (1999) 1.39
Hepatitis B virus infection. Indian Pediatr (1997) 1.39
Reinfection of mice with respiratory syncytial virus. J Med Virol (1991) 1.39
National immunisation days and global eradication of poliomyelitis. Lancet (1999) 1.38
Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine (1999) 1.37
Genetic studies of respiratory syncytial virus temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.36
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis (1995) 1.36
Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection. Am J Epidemiol (1975) 1.34
Cerebral phaeohyphomycosis caused by Chaetomium globosum in a renal transplant recipient. J Clin Microbiol (1989) 1.33
Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N Engl J Med (1977) 1.32
Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr (1976) 1.31
Fatal Mycoplasma pneumoniae infection with isolation of organisms from lung. JAMA (1967) 1.30
Comparative sensitivity of cross-over electrophoresis and complement fixation test for the detection of Australia antigen. Indian J Med Res (1973) 1.29
Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. J Virol (1996) 1.29
The final stages of the global eradication of polio. N Engl J Med (2000) 1.27
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis (1977) 1.26
Blood stream invasion by Vibrio cholerae O139. Lancet (1993) 1.26
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25
Problems with oral poliovaccine in India. Indian Pediatr (1972) 1.23
Serotyping of Streptococcus pneumoniae by agglutination assays: a cost-effective technique for developing countries. Bull World Health Organ (1996) 1.22
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol (1986) 1.22
Major shift in prevalence of non-O1 and El Tor Vibrio cholerae. Lancet (1993) 1.22
Comparison of different culture media and storage temperatures for the long-term preservation of Streptococcus pneumoniae in the tropics. Bull World Health Organ (2003) 1.21
Australia antigen in blood donors in Vellore. Indian J Med Res (1973) 1.21
Respiratory syncytial virus infection in anti-mu-treated mice. J Virol (1991) 1.20
Humoral and cellular immune responses of seronegative children vaccinated with a cold-adapted influenza A/HK/123/77 (H1N1) recombinant virus. Infect Immun (1980) 1.19
Factors affecting immunization coverage levels in a district of India. Int J Epidemiol (1993) 1.19
Clinical profile of AIDS in India: a review of 61 cases. J Assoc Physicians India (1995) 1.19
Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis (1996) 1.19
Appropriate strategy for immunisation of children in India 3. Community-based annual pulse (cluster) immunisation. Indian J Pediatr (1982) 1.18
Chemotactic migration of neutrophils under agarose. Life Sci (1976) 1.18
Parainfluenza 2 virus: increase in hemagglutinin titer on treatment with Tween-80 and ether. Proc Soc Exp Biol Med (1966) 1.16
Electron microscopic studies of respiratory syncytial temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.16
Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis (1981) 1.15
Transferable trimethoprim resistance of Vibrio cholerae O1 encountered in southern India. Trans R Soc Trop Med Hyg (1990) 1.15
Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun (1983) 1.14
Modified latex agglutination test for rapid detection of Streptococcus pneumoniae and haemophilus influenzae in cerebrospinal fluid and direct serotyping of Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis (1996) 1.14
Age-related response to two Haemophilus influenzae type b vaccines. J Pediatr (1982) 1.14
Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) (2003) 1.13
Role of respiratory tract proteases in infectivity of influenza A virus. J Infect Dis (1987) 1.13
Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J Infect Dis (1971) 1.12
Hepatitis B antigen and viral hepatitis type B in India. Bull World Health Organ (1974) 1.12